AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development
View the full release here: https://www.businesswire.com/news/home/20240206590080/en/
- View the full release here: https://www.businesswire.com/news/home/20240206590080/en/
New AstraZeneca facility in Rockville, Maryland (Photo: Business Wire)
The site represents the latest investment in cell therapy for AstraZeneca following collaborations with Quell therapeutics , AbelZeta, Cellectis , and the acquisition of Neogene Therapeutics. - In the US, AstraZeneca’s manufacturing sites focus on the production of small molecules and biologics, harnessing leading pharmaceutical technology and development.
- AstraZeneca is building a cell therapy portfolio that aims to empower and equip the immune system’s T-cells to more effectively fight cancer.
- Beyond this, the company is advancing a pipeline of novel T-cell receptor therapies (TCR-Ts) through Neogene Therapeutics, a wholly owned subsidiary of AstraZeneca.